← Leaderboards
Michael Bradley Drummond
Johns Hopkins University
$10,950,193
Attributed
$16,166,523
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2010–25$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,166,523 · 6
By mechanism
U01$8,175,674 · 1
R01$7,335,438 · 3
K23$650,411 · 1
R13$5,000 · 1
Top collaborators
- Michelle Floris-Moore3 shared
- Ilona Jaspers3 shared
- Meredith C Mccormack1 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Stephen John Gange$36,428,543
- Todd T Brown$33,742,320
- Gypsyamber D'souza$25,879,984
- Joseph B. Margolick$86,818,342
- Leah Helane Rubin$12,441,193
Others in their field
Top investigators on “Participant”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$407,724,307
- Lawrence Corey · Fred Hutchinson Cancer Center$333,313,234
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Albert Lazzarini · California Institute Of Technology$300,431,866
Research focus
ParticipantLung DiseasesSamplingInflammatoryCohortLungCohort StudiesSeveritiesInfectionLeadAcuteAreaHiv InfectionsChronic Lung DiseaseChronic Obstructive Airway DiseaseAffectPathway InteractionsPlasmaEpithelial CellsHigh RiskMediatingFundingBronchoalveolar LavageEnrollment
Grant awards (22)
UNC MACS/WIHS Combined Cohort Study Clinical Research Site$2,752,661
U01 · FY2025 · HL
HIV-Associated Lung Disease: The Role of Nasal Mucosal Immunity and Microbiome$619,771
R01 · FY2025 · HL · contact PI
UNC MACS/WIHS Combined Cohort Study Clinical Research Site$2,702,913
U01 · FY2024 · HL
The Role of Nasal Mucosal Immunity and Microbiome on the Frequent Exacerbation Phenotype of COPD$712,444
R01 · FY2024 · HL · contact PI
HIV-Associated Lung Disease: The Role of Nasal Mucosal Immunity and Microbiome$648,939
R01 · FY2024 · HL · contact PI
UNC MACS/WIHS Combined Cohort Study Clinical Research Site$2,720,100
U01 · FY2023 · HL
The Role of Nasal Mucosal Immunity and Microbiome on the Frequent Exacerbation Phenotype of COPD$760,907
R01 · FY2023 · HL · contact PI
The Role of Nasal Mucosal Immunity and Microbiome on the Frequent Exacerbation Phenotype of COPD$746,929
R01 · FY2022 · HL · contact PI
The Role of Nasal Mucosal Immunity and Microbiome on the Frequent Exacerbation Phenotype of COPD$744,150
R01 · FY2021 · HL · contact PI
Cathelicidin and Vitamin D: Impact on Populations At-Risk and with COPD$444,689
R01 · FY2019 · HL · contact PI
Support for Conferences and Scientific Meetings R13$5,000
R13 · FY2019 · HL · contact PI
Cathelicidin and Vitamin D: Impact on Populations At-Risk and with COPD$506,883
R01 · FY2018 · HL · contact PI
Cathelicidin and Vitamin D: Impact on Populations At-Risk and with COPD$509,880
R01 · FY2017 · HL · contact PI
Cathelicidin and Vitamin D: Impact on Populations At-Risk and with COPD$519,094
R01 · FY2016 · HL · contact PI
Cathelicidin and Vitamin D: Impact on Populations At-Risk and with COPD$416,290
R01 · FY2016 · HL · contact PI
Cathelicidin and Vitamin D: Impact on Populations At-Risk and with COPD$218,576
R01 · FY2016 · HL · contact PI
Cathelicidin and Vitamin D: Impact on Populations At-Risk and with COPD$18,973
R01 · FY2016 · HL · contact PI
Cathelicidin and Vitamin D: Impact on Populations At-Risk and with COPD$467,913
R01 · FY2015 · HL · contact PI
Mechanisms of COPD Subphenotype Development$162,299
K23 · FY2013 · HL · contact PI
Mechanisms of COPD Subphenotype Development$162,704
K23 · FY2012 · HL · contact PI
Mechanisms of COPD Subphenotype Development$162,704
K23 · FY2011 · HL · contact PI
Mechanisms of COPD Subphenotype Development$162,704
K23 · FY2010 · HL · contact PI